Clark Estates Inc. NY lowered its holdings in shares of Smith & Nephew plc (NYSE:SNN – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 685,000 shares of the medical equipment provider’s stock after selling 65,000 shares during the quarter. Smith & Nephew makes up 4.0% of Clark Estates Inc. NY’s holdings, making the stock its 5th largest position. Clark Estates Inc. NY owned about 0.16% of Smith & Nephew worth $21,331,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of SNN. Argonautica Private Wealth Management Inc. increased its stake in shares of Smith & Nephew by 6.3% during the second quarter. Argonautica Private Wealth Management Inc. now owns 10,244 shares of the medical equipment provider’s stock worth $254,000 after purchasing an additional 605 shares in the last quarter. First Trust Direct Indexing L.P. increased its stake in Smith & Nephew by 6.9% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 9,659 shares of the medical equipment provider’s stock worth $301,000 after buying an additional 626 shares in the last quarter. Inspire Advisors LLC increased its stake in Smith & Nephew by 3.0% during the 2nd quarter. Inspire Advisors LLC now owns 22,286 shares of the medical equipment provider’s stock worth $552,000 after buying an additional 639 shares in the last quarter. Townsquare Capital LLC raised its holdings in shares of Smith & Nephew by 5.4% during the third quarter. Townsquare Capital LLC now owns 14,759 shares of the medical equipment provider’s stock valued at $460,000 after acquiring an additional 761 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Smith & Nephew by 8.6% in the second quarter. Rhumbline Advisers now owns 10,365 shares of the medical equipment provider’s stock valued at $257,000 after acquiring an additional 819 shares in the last quarter. 25.64% of the stock is owned by institutional investors and hedge funds.
Smith & Nephew Price Performance
Shares of SNN opened at $25.30 on Wednesday. Smith & Nephew plc has a 52-week low of $23.65 and a 52-week high of $31.72. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. The stock has a fifty day simple moving average of $27.88 and a two-hundred day simple moving average of $27.90.
Analysts Set New Price Targets
Read Our Latest Research Report on SNN
Smith & Nephew Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Stories
- Five stocks we like better than Smith & Nephew
- What Does a Stock Split Mean?
- 2 Generic Drug Stocks Ready to Surge in 2025
- Pros And Cons Of Monthly Dividend Stocks
- 3 Small-Cap Stocks That Are Ready to Rocket Higher
- Most active stocks: Dollar volume vs share volume
- 2 Essential Data Center Solutions Providers Riding the AI Boom
Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNN – Free Report).
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.